IE49184B1 - 3-alkylxanthines,processes for their preparation and compositions for use in the treatment of chronic obstructive airway disease and cardiac disease - Google Patents

Abstract

3-Alkylxanthines characterized by the formula <CHEM> wherein R<1> is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobuty, cyclopentyl of cyclohexylmethyl, and R<2> is hydrogen or methyl, provided that R<2> is methyl when R<1> is n-propyl, n-butyl or isobutyl, or a physiologically acceptable salt thereof, for example the compound 3-cyclopetnyl-3, 7-dihydro-1H-purine-2, 6-dione, have activity against chronic obstructive airway disease or cardiac disease. These compounds are produced by several methods, exemplified by the following one: reacting a compound of the formula <CHEM> with a compound of the formula R<2>-X wherein R<1> and R<2> have the definition given above and X is -COOH, -CONH2 or -OC-O-CO-R2 and, if necessary, submitting the obtained product to dehydration. The starting compounds wherein R<1> is n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cylohexylmethyl are not previously described in teh literature They are prepared by reacting a compound of the formula R<1>NHCONH2 with cyanoacetic acid, cyclising the produced 1-cyanoycetyl-3-R<1>urea with alkali, nitrosing the so produced 1-R<1>-6-aminouracil with HNO2 and reducing the so produced 1-R<1>-5-nitroso-6-aminouracil with H2//PtO2.

Description

The present invention relates to novel, pharmacologically active compounds and methods for their preparation. The invention also relates to pharmaceutical compositions containing the compounds. More 5 particularly, the novel compounds of the invention are intended for use in the treatment of chronic obstructive airway disease (COAD) or cardiac disease.

The object of the present invention is to provide xanthine derivatives which have a bronchodilatory and cardiotonic potency but which do not elicit convulsions. Background Art Theophylline and various salts thereof are used in the treatment of chronic obstructive airway disease (COAD) and cardiac disease. Major therapeutic effects of theophylline are to relax bronchial smooth muscle and stimulate heart muscle. The major drawback with theophylline therapy is that the drug with a significant frequency produces toxic side-effects; most common are nausea and gastric distress, most serious are convulsions, which may lead to death.

Xanthine derivatives substituted with methyl in position 1 are disclosed in U.S. 4089959 as having bronchodilatory activity.

Disclosure of the Invention It has been found according to the present invention that compounds of the formula: χ X* ΗΝ^ R and the physiologically acceptable salts thereof, wherein R is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl, and R is hydrogen or methyl, 2 · 1 provided that R is methyl when R is n-propyl, n-butyl or isobutyl, possess bronchodilatory and cardiotonic potency but do not elicit convulsions. This advantageous property makes the compounds of the invention valuable in the treatment of chronic obstructive airway disease (COAD) and of cardiac disease.

The present invention includes pharmaceutically acceptable salts of compounds of formula (1) with pharmaceutically acceptable bases. By the term pharmaceutically acceptable salts is meant salts the cations of which are relatively innocuous to the animal organism when used in therapeutic doses so that the beneficial pharmacological properties of the parent compounds of general formula (1) are not vitiated by side effects ascribable to those cations. Suitable salts include the alkali metal, e.g. sodium and potassium, and ammonium salts and salts of amines known in the art to be pharmaceutically acceptable, e.g. glycine, ethylene diamine, choline, diethanolamine, triethanolamine, 1-amino-2-propanol-2-amino -2-(hydroxymethyl)propane-1,3-diol and 1-(3,4-dihydroxyphenyl) -2-isopropylaminoethanol.

Pharmaceutically acceptable salts may be prepared by the reaction together of stoichiometric quantities of a compound of formula (1) and the appropriate base, that is to say, a base as described immediately hereinbefore, for example at an elevated temperature, with or without an appropriate solvent, preferably followed by recrystallisation from an appropriate solvent, for example a hydroxylic solvent, e.g. water, of the salt so formed.

In clinical practice the compounds of the present invention will normally be administered orally, rectally, nasally, sublingually, by injection or by inhalation in the form of a pharmaceutical preparation comprising the active ingredient in the form of the original compound or optionally in the form of a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier which may be a solid, semi-solid or liquid diluent or an ingestible capsule, and such preparations comprise a further aspect of the invention. Usually the active substance will comprise between 0.1 and 99% by weight of the preparation, for example between 0.5 and 20% for preparations intended for injection and between 0.1 and 50% for preparations intended for oral administration.

To produce pharmaceutical preparations in the form of dosage units for oral application containing a compound of the invention the active ingredient may be mixed with a solid, pulverulent carrier, for example lactose, saccharose, sorbitol, mannitol, a starch such as potato starch, corn starch, amylopectin, laminaria powder or citrus pulp powder, a cellulose derivative, polyvinylpyrrolidone or gelatin and also may include lubricants such as magnesium or calcium stearate or a Carbowax^or other polyethylene glycol waxes and compressed to form tablets or cores for dragSes, if drag6es are required, the cores may be coated, for example with concentrated sugar solutions which may contain gum arabic, talc and/or titanium dioxide, or alternatively with a film agent dissolved in easily volatile organic solvents or other suitable solvent or mixtures of organic solvents. Dyestuffs can be added to these coatings for example, to distinguish between different contents of active substance.

For the preparation of soft gelatin capsules (pearl-shaped closed capsules) consisting of gelatin and, for example, glycerol as a plasticizer, or similar closed capsules, the active substance may be admixed with a Carbowax® or a suitable oil as e.g. sesam oil, olive oil,'or arachis oil. Hard gelatin capsules may contain granulates of the active substance with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches (for example potato starch, corn starch or amylopectin), cellulose derivatives, polyvinylpyrrolidone or gelatin, and may also include magnesium stearate or stearic acid as lubricants.

A compound of the invention may also be formulated as a sustained action dosage form using suitable excipients. Different methods may be used for the availability control e.g. diffusion process and ion exchange. Methods using the diffusion process may be exemplified by products involving coated granules or particles, matrix imbedded drug and slightly soluble forms.

Effervescent powders are prepared by mixing the active ingredient with non-toxic carbonates or hydrogen carbonates of e.g. sodium, potassium or calcium, such as calcium carbonate, potassium carbonate and potassium hydrogen carbonate, solid, non-toxic acids such as tartaric acid, ascorbic acid, and citric acid, and for example aroma.

Liquid preparations for oral application may be in the form of elixirs, syrups or suspensions, for example solutions containing from about 0.1% to 2055 by weight of active substance, sugar and a mixture of ethanol, water, glycerol, propylene glycol and optionally aroma, saccharin and/or carboxymethylcellulose as a dispersing agent.

For parenteral application by injection preparations may comprise an aqueous solution or suspension of the active substances according to the invention, desirably in a concentration of 0.5-10S, and optionally also a stabilizing agent and/or buffer substances in aqueous solution. Dosage units of the solution may advantageously be enclosed in ampoules.

Ihe dosage at which the active ingredients are administered may vary within a wide range and will depend on various factors such as for example the individual requirements of each patient. A suitable oral dosage range is from 50 to 1000 mg given 1-4 times a day. A suitable dosage range at parenteral aministration is from 20 to 500 mg The pharmaceutical compositions containing the active ingredients may suitably be formulated so that they provide doses within these ranges either as single dosage units or as multiple dosage units.

The compounds of the invention can be prepared by any of the following methods.

A. Reacting a compound of the formula: HN' 'C-NH, x'C-NH, with a compound of the formula: wherein R is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methyl butyl, 5-methylbutyl, 2,2-dimethylpropy1, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexylmethyl, R is hydrogen or methyl, X is -COOH, -CONH, or -0C-0-C0-R2, provided that 2 1 2 R is methyl when R is n-propyl, n-butyl or isobutyl and, if necessary, submitting the obtained product to dehydrat i on.

The dehydration may be carried out for instance by 25 heating the reaction mixture in the absence of solvent or by heating the mixture with alkali or by boiling the mixture in a high-boiling solvent.

The starting material of the compounds prepared according to this route can be obtained for instance as illustrated in the reaction scheme below, wherein the 1 radical R has the meaning given in this specification. 48184 NHgCONH-R CNCHgCOOH Η^Ί oh Ο II ΓΊ -NO \ XC-NH2 PtOg/Hg • 49184 B. Reacting a compound of the formula: 0 li HtV '''C-NH, I II 2 l· with a compound of the formula: rZ-x* 1 wherein R is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl, or cydohexylmethyl, R 1 is hydrogen or methyl, X is -CKO or provided that R is methyl when R is n-propyl, n-butyl or isobutyl, and submitting the obtained product to oxidative cyclization. j Q is hydrogen or an alkyl group with 1-3 carbon atoms and Q is an alkyl group with 1-3 carbon atoms. Preferably 1 2 Q and Q are methyl or ethyl.

For the oxidative cyclization a variety of agents can be used, e.g. thionyl chloride, SOC^· Intermediates The compounds of the formula: J KN^ '''C-NH, 1 II - C -C-NH, ^N-^ 2 0 '1 - R wherein R is n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,220 dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cydohexylmethyl are not previously described in the literature. They are valuable starting materials for the 48184 preparation via methods A and B of the compounds of the invention. The preparation of the starting material is described in connection with the description of method A.

Best Mode of Carryinq Out the Invention The best result when carrying out this invention will be obtained when the compound 3-cyclopenty1-3,7-dihydro-1Hpurine-2,6-dione is used.

Working Examples Example 1. Preparation of 3-cyclopropyl-3,7-dihydro-1Hpurine-2,6-dione VI a) Preparation of 6-amino-1-cylopropyl-2,4-(1H,3H)pyrimidinedione 11.

To a solution of 64g (0.75 mol) cyanoacetic acid and 250 ml of acetic anhydride was added 70g (0.7 mol) of cyclopropylurea. The solution was stirred at 60-70°C for 2 hours. After cooling white crystals were filtered off and washed with ethanol. Yield 76.7 g (668ί) (I). This was suspended in 200 ml of hot water and 55 ml of 5 N NaOH was added in portions so the solution the whole time was basic. The reaction mixture was refluxed for 20 minutes and then neutralized with 5 N HC1. After cooling, white crystals were filtered off. Yield 31.7 g (428) (II) NMR. b) Preparation of 6-amino-1-cvciopropyl-5-nitroso-2,4(1H.3H)-pyrimidinedione III, 31.7 g (0.19 mol) of 6-amino-1-cyclopropyl-2,420 (1Η,3H)-pyrimidinedione (II) was suspended in 250 ml water.

To this was added 45 ml of 5 N HC1 and 15 g 6f NaNO^ (0.22 mol) which was dissolved in water. The reaction mixture was stirred for 2 hours end after cooling, the red crystals were filtered off and washed with water. Yield 31.9 g (868) (III) NMR. c) Preparation of 1-cyclopropyl-5,6-diatnino-2.4-(1 Η, 3H)pyrimidinedione TV. .9 g of 6-amino-1-cyclopropyl-5-nitroso-2,Αυ Η , 3H ) -pyrimidinedione (III) was catalytically hydrogenated in 1 liter of DMF and in the presence of 0.1 g Pt02 for 4 hours and at room temperature and at a pressure of 200 kPa. Ihe catalyst and the crystals were filtered off and washed with ethanol. Yield 12.9 g (87%) (IV). d) Preparation of 3-cyclopropy1-3,7-dihydro-1H-purlne-2,610 dione VI, Λ solution of 12 g of 1-cyclopropyl-5,6-diamino-2,4(1 Η,3H)-pyrimidinedione (IV) in 50 ml of formic acid was refluxed for 2 hours. The hot solution was filtered and 30 ml of chloroform was added and ether was then added slowly. The received crystals were filtered off. Yield 11.2 g (V). The amide (V) was refluxed in 40 ml of 2 N NaOH for 1 hour and then neutralized with 5 N HCl. The crystals were filtered off. Yield 7g (60%) (VI) NMR (see Table I). 48184 Reaction scheme: NHgCONH NCCHgCOOH Ex 1 a /'k NaOH HIT C-H Ex 1 a ^ϋ-NHg ex 1 b N II Ex 1 c -> HN/C'XC-NHZ HCOOH Ex 1 d HN/^C-NHC-H J. « —* X\N/l-NH2 VI Example 2. Preparation of 3-cyclobutyl-3,7-dihydro-1Hpurine-2,6-dione XII. a) Preparation of 6-amino-1-cyclobutyl-2,4-(1 Η,3H)~ pyrimidinedione VIII.

To a solution of 30 g (0.35 mol) cyanoacetic acid and 1D0 ml of acetic anhydride was added 36.1 g (0.32 mol) of cyclobutylurea. The solution was stirred at 60-70°C for 2 hours. After cooling, white crystals were filtered off and washed with ethanol. Yield 36.4 g (63½) (VII). This was suspended in 100 ml of hot water and 50 ml of 2 N NaOH was added in portions so the solution the whole time was basic. The reaction mixture was refluxed for 20 minutes.

After cooling, white crystals were filtered off. Yield 3.6 g (20%) (VIII) NMR. b) Preparation of 6-amino-1-cyclobutyl-5-nitroso-2,4(1Η,3H)-pyrimidinedione IX. 3g (0.0166 mol) of 6-amino-1-cyclobutyl-2,4(1Η,3H)-pyrimidinedione (VIII), was suspended in 25 ml water. To this was added 4 ml of 5 N HC1 and 1.3 g of NaN02 (0.019 mol) which was dissolved in water. The reaction mixture was stirred for 3 hours and the red crystals were filtered off and washed with water. Yield 3.1 g (89%) (IX) NMR. c) Preparation of 1-cyclobutyl-5,6-diamino-2,4-(1Η,3H)pyrimidinedione X. 6.9 g of 6-amino-1-cyclobutyl-5-nitroso-2,4-(1Η,3H) 25 pyrimidinedione (IX) was catalytically hydrogenated in 250 ml of DMF and in the presence of 0.1 g Pt02 for 2 hours and at room temperature and at a pressure of 200 kPa. The catalyst and the crystals were filtered off and washed with ethanol. Yield 3.5 g (54%) (X). d) Preparation of 3-cyclobuty1-3,7-dihydro-1H-purine-2,6dione XI11.

A solution of 3.5 g of 1-cyclobutyl-5,6-diamino-2,4(1Η,3H)-pyrimidinedione (X) in 20 ml of formic acid was refluxed for 2 hours. The hot solution was filtered and ml of chloroform was added and ether was then added slowly. The received crystals were filtered off. Yield 2.7 g (XI).

The amide (XI) was refluxed in 20 ml of 2 N NaOH for 5 1 hour and then neutralized with 5 N HCl . The crystals were filtered off and recrystallized from 150 ml ethanol. Yield 1.4 g (38,%') (XII) NMR (see Table I).

Reaction scheme: nh2conh NCCH-COOH r -7-7-^H2 " Ex 2 a I 2 ,p C=-N \ NH VII II NaOH hZ ^C-H ——» I 1 7V^ VIII II /C HCOOH Ex 2 c > H^l ΐ zcXnX-nh2 -NH, Ex 2 d hZ ^C-NHC-H I II XI tl H NaOH Ί Χ C\N/C ^N X <> XII Example 3. Preparation of 3-cyclopentyl-3,7-dihydro-1H purine-2,6-dione XVIII. a) Preparation of 6-amino-l-cyclopentyl-2,4-(1H,3H)~ pyrimidinedione XIV.

To a solution of 136 g (1.6 mol) cyanoacetic acid and 400 ml of acetic anhydride was added 192 g (1.5 mol) of cyclopentyl-urea. The solution was stirred at 60-70°C for hours. After cooling white crystals were filtered off and washed with ethanol. Yield 192 g (66%) (XIII). This was stirred in 500 ml of hot water and 195 ml of 5 N NaOH was added in portions so the solution the whole time waa basic. The reaction mixture was refluxed for 20 minutes and then neutralized with 5 N HC1. After cooling, white crystals of cyclopentyiurea were filtered off (159 g). The filtrate was evaporated and the residue was refluxed with 200 ml of 1 N NaOH. After cooling the cyclopentyiurea was filtered off and the filtrate was neutralized with 5 N HC1. The crystals were filtered off. Yield 3.8 g (2%) (XIV) NMR. b) Preparation of 6-amino-1-cyclopentyl-5-nitroso-2,4(1H,3H)~ pyrimidinedione XV. 12.4 g (0.064 mol) of 6-amino-1-cyclopentyl-2,4(1H,3H)-pyrimidinedione (XIV) was suspended in 200 ml water. To this was added 14 ml of 5 N HCl and 4.8 g of NaN02 (0.07 mol) which was dissolved in water. The reaction mixture was stirred for 1 hour and washed with water. Yield 12.9 g (90%) (XV) NMR. c) Preparation of 1-cyclopentyl-5,6-diamino-2,4-(1Η,3H)pyrimidinedione XVI. 12.9 g of 6-amino-1-cyclopentyl-5-nitroso-2,4(1H,3H)-pyrimidinedione (XV) was catalytically hydrogenated in 30 ml of 2 N HCl and in the presence of 0.1 g Pt02 for hours and at room temperature and at a pressure of 200 kPa. The catalyst was filtered off and the filtrate was neutralized with 5 N NaOH. The crystals were filtered off. Yield 6.1 g (50%) (XV). d) Preparation of 3-cycIopentyl-3,7-dihydro-1H-purine-2,6di one XVI11.

A solution of 6.1 g of 1-cyclopentyl-5,6-diamino2,4-(1H,3H)-pyrimidinedione (XVI) in 25 ml of formic acid was refluxed for 1 hour. The hot solution was filtered and 20 ml of chloroform was added and ether was then added slowly. The received crystals were filtered off. Yield 5.9 g (XVII), The amide (XVII) was refluxed in 30 ml of 2 N NaOH for 1 hour and then neutralized with 5 N HL'l The crystals were filtered off and recrystallized from 400 ml ethanol. Yield 3.4 g (532ί) (XVIII) NMR (see Table I).

Reaction scheme: NHgCONH NaOH -> Ex 3 a u .1 XIV -» Ex 3 c H XVIII Example 4. Preparation of 3,7-dihydro-3-eyclohexylmethyl-1H-purine-2,6-dione XXIV. a) Preparation of 6-amino-1-cyclohexylmethyl-2,4-(1Η,3H)pyrimidine-dione (XX) was performed according to the description of Example 3 a. b) Preparation of 6-emino-1-cyclohexylmethyl-5-nitroso-2,45 - (1Η,3H)-pyrimidinedione (XXI) was performed according to the description of Example 3 b. c) ' Preparation of 5,6-diamino-1-cyclohexylmethyl-2,4-(1Η,3H)pyrimidinedione (XXII) was performed according to the description of Example 2 c. d) Preparation of 3,7-dihydro-3-cyclohexylmethyl-1H-purine2,6-dione XXIV. g of 5,6-diamino-1-cyclohexylroethyl-2,4-(1H,3H)pyrimidine dione (XXII) was refluxed in 10 ml of formic acid for 1 h. 5 ml of chloroform was added and ether was then added slowly. The received crystals were filtered off. Yield 2.1 g (XXIII). The amide (XXIII) was refluxed in 15 ml of 2 h NaOH for 1 hour and then neutralized with 5 N HCl Yield 1.7 g (XXIV) NMR (see Table I).

Reaction scheme: ncch2cooh Ex 4 a NH CH.

XXX CH, Ex 4 c > Ό-™2 HCOOH Ex 4 d C-NH.

XXI XXIV Example 5. Preparation of 3,7-dihydro-3-(2,2-dimethylpropyl)-1H-purine-2,6-dione XXIX. a) Preparation of 6-amino-1-(2,2-dimethylpropy1)-2,4-(1 Η,3H)pyrimidinedione (XXVI) was performed according to the description of Example 3 a. b) Preparation of 6-aroino-1-(2,2,-dimethylpropyl)-5-nitroso5 -2,4-(1Η,3H)-pyrimidine dione (XXVII).

To a solution of 7.0 g of XXVI in 50 ml of DMSO was added 8 ml of 5 N HCl and 2.7 g of NaN02 dissolved in 5 ml of water. The reaction mixture was stirred 10 minutes at 50°C and then 100 ml of water was added. The red crystals were filtered off. Yield 6 g (XXVII). c) Preparation of 5,6-diamino-1 -(2,2-dimethylpropyl)-2,4(1H,3H)-pyrimidinedione (XXVIII).

To a suspension of 6.0 g of XXVII in 100 ml of water was added 13.0 g of sodium dithionite in portions. The green crystals were filtered off and washed with water. Yield 4.0g (XXVIII). d) Preparation of 3,7-dihydro-3-(2,2,-dimethylpropyl)-1Hpurine-2,6-dione (XXIX). 4.0 g of XXVIII was refluxed in 20 ml of formamide 20 fo 30 minutes. After cooling 30 ml of ethanol was added and the yellow crystals were filtered off and recrystallized from 15 ml of DMF. Yield 2.0 g (XXIX) NMR (see Table I).

Reaction scheme: 48184 CH, nh2conh-ch2-c-ch3 NCCH2COOH NaOH Ex 5 a CH, j/V‘ I CH, CH, Ex 5 a NH2 Ex 5 b CH, XXVI NH2CHO Ex 5 d XXVIII ? HNxCxCH, I Sn /Sh ° £*h2 I 2 CH3 - (j - CHj CH, ‘3 XXV NO ^cx /C-NH2 ch2 CH, - C - CH, 3 I 3 CHj XXVII tjH2 c I CH, CH, - C - CH, 3 I 5 XXIX Example 6. Preparation of 3,7-dihydro-8-methyl-3-cyclohexylmethyl-1H-purine-2,6-dione XXX. 1g of 5,6-diamino-1-cyclohexylmethyl-2,4-(1Η,3H)pyrimidine dione (XXII) was refluxed in 5 ml of acetic acid for 1 hour. 2 ml of chloroform was added and ether was then added slowly. The received crystals of the amide were filtered off. Yield 1 g.

The amide was refluxed in 10 ml of 2 N NaOH for 1 hour and then neutralized with 5 N HCl The crystals were filtered off and reerystallized from 80 ml of ethanol. Yield 0.6 g (XXX) NMR (see Table I).

Example 7. Preparation of 3-cyclopentyl-3,7-dihydro-8methyl-1H-purine-2,6-dione XXXI. 1.6 g of 1-cyclopentyl-5,6-diamino-2,4-(1Η,3H)pyrimidine dione (XVI) was refluxed in 10 ml of acetic acid for 15 min. 10 ml of chloroform was added and ether was then added slowly. The received crystals of the amide were filtered off. Yield 2.0 g, The amide was refluxed in 5 ml of 2 N NaOH for 1 hour and then neutralized with 5 N HCl The crystals were filtered off and reerystallized from 25 ml of 80% ethanol. Yield 0.7 g (XXXI) NMR (see Table I).

Example 8. Preparation of 3,7-dibydro-3-(2,2-dimethylpropy1)8-methy 1-1H-purine-2,6-dione XXXIV. .4 g of 5,6-diamino-1-(2,2-dimethylpropyl)-2,420 (1Η,3H)-pyrimidine dione (XXVIII) was refluxed in 75 ml of acetic acid for 1 hour. 50 ml of chloroform was added and ether was then added slowly. The received crystals were filtered off. Yield 11.4 g. The amide was refluxed in 50 ml of 1 N NaOH for 1 hour and then neutralized with N HCl Yield 7.2 g (XXXIV). NMR (see Table I). 48184 Example 9. Preparation of 3,7-dihydro-8-methyl-3-(2-methylpropyl)-1H-purine-2,6-dione XXXV. g of 5,6-diamino-1-(2-methylpropyl)-2,4-(1H,3H)pyrimidine dione was re fluxed in 50 ml of acetic acid for 1 hour. 30 ml of chloroform was added and ether was then added slowly. The received crystals were filtered off.

Yield 10.8 g. The amide was refluxed in 30 ml of 2 N NaOH for 1 hour and then neutralized with 5 N HCl The crystals were filtered off and recrystallized from 50 ml of acetic acid. Yield 3.3 g. NMR (see Table I). 4-918 4 TABLE I NMR data in S' Solvent DMSO-dg (g = 2.83) r3 r8 Nih n7h Ex 1d D 4161 (VI) 1H 3,20 m 4H 1,22 m 1H 8, 35s 11,23b 13,80b Ex 2d D 4164 (XII) 4H 2,36 in 1H 5,42 p 2H 3,43 p 1H 8,40s 11,43b 13,83b Ex 3d D 4132 (XVIII) 1H 5,53 p 8H 2,17 m 1H 8,40s 11,43b 13,94b Ex 4d D 4138 (XXIV) 2H 4,14 d 11H 1,63 m 1H 8,37s 11,37b 13,90b Ex 5d D 4034 (XXIX) 2K 4,16 s 9H 1,23 s 1H 8,27s 11,40b 13,84b Ex 6 D 4137 (XXX) 2H 4,10 d 11H 1,60 m 3H 2,70s 11,Z7b 13,45b Ex 7 D 4134 (XXXI) 1H 5,50 p 8H 2,20 in 3H 2,68s 11,30b 13,43b Ex Θ D 4070 (XXXIV) 2H 4,08 s 9H 1,23 s 3H 2,67s 11,24b 13,40b Ex 9 D 4169 (XXXV) 2H 4,05 d 3H 2,63s 11,10b 13,27b 1H 2,50 h 6H 1,10 d The following Examples illustrate how the compounds of the invention can be incorporated in pharmaceutical compositions.

Example 10. Aerosol for inhalation.

Active substance Miglyol (Registered Trade Mark) Frigen (Registered Trade Mark) 11/12/113/114 1.50 g 0.20 g ad 100.0 g Frigen is used to denote the halogenated hydrocarbons. Frigen 114 is 1,2-dichloro-1,1,2,2tetrafluorethane, Frigen 113 is 1,1-difluoro-2,2dichlorotrifluorotrichloroethane, Frigen 11 is trichloromonofluoromethane and Frigen 12 is dichlorodifluoromethane. Miglyol denotes a triglyceride of saturated vegetable oils. Or a pulver aerosol where the active substance is mixed with lactose.

Example 11. Tablets.

Each tablet contains: Active substance 20.0 mg Maize starch 25.0 mg Lactose 190.0 mg Gelatin 1.5 mg T ale 12.0 mg Magnesium stearate 1.5 mg 250.0 mg Example 12. Suppositories.

Each suppository contains: Active substance 50.0 mg Ascorbyl palmitate 1.0 mg Suppository base (Imhausen H) ad 2.000.0 mg 184 Example 13. Injection solution.

Active substance 2.000 mg Sodium hydroxide 0.310 mg Sodium pyrosulphite 0.500 mg Disodium edetate 0.100 mg Sodium chloride 8.500 mg Sterile water for injection ad 1,00 mg Example 14. Sublingual tablets.

Each tablet contains: Active substance 20.0 mg Lactose 85.0 mg 10 Agar 5.0 mg Talc 5.0 mg Pharmacological Tests.

Acute toxicity studies in mice.

Male NMRI mice, weighing 20-26 g, starved for 6 h were used. The compounds, dissolved in 0.5 M NaOH and 0.85% NaCl-solution (pH 10.6-12.1) were administered as follows : a) intravenously, 0.1 ml/10 g at an injection rate of 0.3 ml per minute b) orally, 0.1 ml/10 g At least seven dose levels, doses increasing in a 20 geometric progression with a factor 1.2, were examined.

Each dose was given to 5 animals. The animals were observed for signs of toxicity during 14 days after administration. The position of extremities in dead animals indicated whether they had died in convulsions or not.

In acute toxicity studies it was observed that many xanthine compounds elicit convulsions. This was also repeatedly shown to occur with theophylline. However, 48184 no sign of convulsive activity (such as tonically stretched hindlegs of dead animals) was observed in animals given the compounds of this invention.

Additionally, convulsive activity was studied by slowly infusing drugs into the tail veins of albino mice.

In this study it was confirmed that alkyl substituted xanthines (theophylline and caffeine) consistently produced tonic convulsions, and that with the compounds of the invention death occurred without signs of tonic convulsions. (Table II).

Isolated guinea-pig trachea.

Guinea-pigs of both sexes, weighing between 150 and 250 g, were killed by a blow on the head and bled. The trachea was removed and cut spirally yielding one or two preparations. The tracheal preparations were mounted in organ baths containing Krebs solution maintained at 37°C and bubbled with carbogen (95% 0g + 5% COg). Isometric tension reflecting mainly activity in circular tracheal muscle wag recorded by means of a force displacement transducer. Initial tension was set at 0.5 g which was the approximate basal tension kept during the experiment. Evaluation of relaxant effects was done when the preparations had contracted to a stable tension by the addition of carbacholine 0.1 pg/ml to the bath. EC^g values, i.e. molar concentrations of xanthines required to produce 50% maximum response were obtained from log concentration response lines and used to calculate the potency of theophylline relative to that of the test drug. After washing out the drugs the trachea resumed its baspl tone and was left to stabilize for at least 15 min. before the next drug evaluation was performed. Between two evaluations of theophylline the effect of the test drug was examined and its EC^g value was compared with the mean of the previous and following ECjg values of theophylline. In the Table II the potency rations are illustrated. Theophylline is one by definition and a value larger than one indicate that the drug is more potent than theophy11ine.

Isolated Guinea-Pig Hearts From the bled guinea-pigs, the hearts were immediately removed and perfused with oxygenated Krebs solution at 37° according to Langendorff. The heart was mounted in a thermostatically controlled organ bath (25 ml) containing Krebs solution. A saline-filled, open end polyethylene catheter was inserted into the right ventricle through the pulmonary artery. The catheter was fixed to the pulmonary artery by a ligature just above the valvular plane. It was connected to a pressure transducer (P23 AC), making it possible to record changes in intraventricular pressure. From these, the contraction frequency was obtained. Drugs were given as single bolus injections into the perfusion solution.

Compound Guinea-Pig Convulsion test Death mg/kg i.e. Guinea-Pig trachea mice i.v. heart Potency Effects Potency ratios of ratios of c •rt O. O rl tt >,44 £ o α. ε o o \0 0\ + « ΓΑ lA O Ps ps Ps \D »0\ -4- iA ιΛ fA •tf M3 CM P* vo M3 CM «" cm fA •h +t fA M3 0\ fA fA t- ch 0) tt tt υ υ o c c c <0 CO CO > > O c C C Λ q Ο Ο Ή o 0 u- +J O to UQ US > rt fA -rt CM CO -H C\ C'x CO —4 o O OS O CS 4_) fA 44 CM »—I CO O' O\ T<— PM • 41 fA fA Ch Ch M3 · «- Ch fA CM Ή • a Ch fA <- o tA rtt u c (0 tt υ c CS CO CM CO CO •ίa esc a c λ λ ο £ ο •rt Ή U~ U~ 44 U- 44 ο o to o a > > co CO 'rt OT 'rt OT OT *-4 tO *rt Ο Ο » O (8 -rt ·-» OT --1 « O C 43 O •rt U- 44 o a > η ή r4 o a -1 co c o tt u u c u CO -rt F-ί C (0 o £ 44 \ (»- u Ο -H c*-> CO o o « Ή ΤΟ u\ -rtsxfA £ tt Ϊ > tt c a o c o co wrt a ot rt £ C tt tt c ^4 c n ,rI tt -rt O M tt σ» ot COOT •rt C O 03 CO —1 OT n o O' c •rt OT VI - 3-cyclopropy1-3,7-dihydro-1H-purine-2,6-dione XII = 3-cyclobutyl-3,7-dihydro-1H-purine-2,6-dione XVIII = 3-cyclopentyl-3,7-dihydro-1H-purine-2,6-dione XXIV = 3,7-dihydro-3-cyclohexylmetbyl-1H-purine-2,6-dione XXIX = 3,7-dihydro-3-(2,2-dimethylpropyl)-1H-purine-2,6dione XXX = 3,7-dihydro-8-methyl-3-cyclohexylmethyl-1H-purine-2,6 dione XXXI - 3-cyclopentyl->,7-dihydro-8-methyl-1H-purine-2,610 dione XXXIV = 3,7-dihydro-3-(2,2-dimethylpropy1)-8-methyl-1Hpurine-2,6-dione.

XXXV = 3,7-dihydro-8-methy1-3-(2-methylpropyl)-1H-purine2,6-dione Lengend to Table The left column lists molar potency ratios for bronchodilation between theophylline and various xanthine compounds. Toxic symptoms occuring before death in mice receiving constant rate infusion of drug i.v. are accounted for in the middle column. Tonic convulsions (conv.) is a consistent effect by theophylline and caffeine (30 out of 30 and 20 out of 20 respectively tested animals had marked tonic convulsions). Each other compound was tested in 10 animals and in no case a tonic convulsion was induced.

The notes indicate, however, that a few animals receiving D 4164, D 4161 or D 4169 exhibited a clonic-type of convulsion or a mixed clonic/tonic type of convulsion, however, of very moderate intensity compared to the effect seen by theophylline and caffeine. The far right column indicate cardiotonic activity as positive chronotropic potency.

Claims (17)

1. A compound of the formula: A/' LA or a physiologically acceptable salt thereof, in which 1 formula R is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl 2. 2 and R is hydrogen or methyl, provided that R is methyl when R is n-propyl, n-butyl or isobutyl.

2. A compound according to claim 1 with the 10 formula: AU τ i \„ R 11 or a physiologically acceptable salt thereof, wherein R is n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl.

3. A compound according to claim 1 with the formula: 0 H N c-c» 3 fcf' or a physiologically acceptable salt thereof, wherein R is n-propyl, n-butyl, isobutyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexylmethyl.

4. A compound according to claim 1 hereinbefore specifically mentioned.

5. A compound according to claim 1 in which R is cyclopentyl and R is hydrogen. 5

6. A method for the preparation of a compound as defined in claim 1 the formula: which comprises reacting a compound of (I - NH 2 n ^ C \ N / C - NH 2 0 '1 R the formula: as defined in claim 1 and X is -COOH with a compound of 1 2 wherein R and R ι -CONHg or -OC-O-CO-R and, if necessary, submitting the resulting product to dehydration.

7. A method for the preparation of a compound as 15 defined in claim 1 which comprises reacting a compound of the formula: NHg NHg with a compound of the formula: 12 1 wherein R and R are as defined in claim 1 and X is j wherein Q is hydrogen or an alkyl group with 1 to 3 carbon 2 atoms and 0 is an alkyl group with 1 to 3 carbon atoms, and then submitting the resulting product to oxidative cyclization.

8. A method according to claim 6 or 7 wherein the resulting product is converted into a physiologically acceptable salt by reaction with a physiologically acceptable base.

9. A method according to any one of claims 6 to 8 wherein a compound according to any one of claims 2 to 5 is prepared.

10. A method according to any one of claims 6 to 8 substantially as hereinbefore described with reference to any one of Examples 1 to 9.

11. A compound or salt as defined in claim 1 obtained by a method according to any one of claims 6 to 10.

12. A pharmaceutical preparation comprising as active ingredient as effective amount of a compound or salt according to any one of claims 1 to 5 and 11 in association with a pharmaceutically acceptable carrier for use in the treatment of chronic destructive airway disease or cardiac disease .

13. A pharmaceutical composition comprising as active ingredient a compound or salt according to any one of claims 1 to 5 and 11 together with a pharmaceutically acceptable carrier.

14. A composition according to claim 12 or 13 in dosage unit form.

15. A composition according to claim 12, 13 or 14 substantially as hereinbefore described with reference to any one of Examples 10 to 14.

16. a method for the treatment of chronic obstructive airway disease in mammals excluding man which comprises administering an effective amount of a compound or salt according to any one of claims 1 to 5 or 11 or a composition according to any one of claims 13 to 15.

17. A method for the treatment of cardiac disease in mammals excluding man which comprises administering an effective amount of a compound or salt according to any one of claims 1 to 5 or 11 or a composition according to 5 any one of claims 13 to 15.